Coexistence of gastrointestinal stromal tumours (GIST) and malignant neoplasms of different origin: Prognostic implications

Vassos, Nikolaos; Agaimy, Abbas; Hohenberger, Werner; Croner, Roland S.

doi:10.1016/j.ijsu.2014.03.004

Cited by 54 publications

(53 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The largest study including 783 patients of one institutional tumor registry reported a rate of secondary neoplasms in 20% [22] . In contrast, very recently 43% of secondary neoplasms have been reported of a GIST cohort including only 86 patients [26] . Systematic work is missing regarding patient outcome and the assessment of overall survival (OS), disease specific survival (DSS) and disease free survival.…”

Section: Introductionmentioning

confidence: 93%

Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors

Kramer¹,

Wolf²,

Mayer³

et al. 2015

Neoplasia

View full text Add to dashboard Cite

Currently available data on prognostic implication of additional neoplasms in GIST miss comprehensive information on patient outcome with regard to overall or disease specific and disease free survival. Registry data of GIST patients with and without additional neoplasm were compared in retrospective case series. We investigated a total of 836 patients from the multi-center Ulmer GIST registry. Additionally, a second cohort encompassing 143 consecutively recruited patients of a single oncology center were analyzed. The frequency of additional malignant neoplasms in GIST patients was 31.9% and 42.0% in both cohorts with a mean follow-up time of 54 and 65 months (median 48 and 60 months), respectively. The spectrum of additional neoplasms in both cohorts encompasses gastrointestinal tumors (43.5%), uro-genital and breast cancers (34.1%), hematological malignancies (7.3%), skin cancer (7.3%) and others. Additional neoplasms have had a significant impact on patient outcome. The five year overall survival in GIST with additional malignant neoplasms (n = 267) was 62.8% compared to 83.4% in patients without other tumors (n = 569) (P < .001, HR=0.397, 95% CI: 0.298-0.530). Five-year disease specific survival was not different between both groups (90.8% versus 90.9%). 34.2% of all deaths (n = 66 of n = 193) were GIST-related. The presented data suggest a close association between the duration of follow-up and the rate of additional malignancies in GIST patients. Moreover the data indicate a strong impact of additional malignant neoplasms in GIST on patient outcome. A comprehensive follow-up strategy of GIST patients appears to be warranted.

show abstract

Section: Introductionmentioning

confidence: 93%

Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors

Kramer¹,

Wolf²,

Mayer³

et al. 2015

Neoplasia

View full text Add to dashboard Cite

show abstract

“…While the majority of these tumors are thought to arise spontaneously, approximately 5% are considered hereditary . There are multiple single institution and population based studies that have shown GIST patients to have an increased risk of developing additional malignancies, including renal cell carcinoma . Similar to GISTs, a minor proportion (5‐8%) of RCCs are known to occur due to hereditary etiology, and some with an identifiable genetic abnormality .…”

Section: Introductionmentioning

confidence: 99%

The association of renal cell carcinoma with gastrointestinal stromal tumors

Mendonca

Sánchez

Blum

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives Prior small studies have reported a possible association between renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GISTs). In the largest known series, our objective was to describe the prevalence of RCC among patients with GISTs over 26 years at Memorial Sloan Kettering Cancer Center (MSKCC). Methods We retrospectively reviewed MSKCC’s prospectively maintained sarcoma and RCC databases and identified all patients with both RCC and GIST between 1980 and 2016. Demographic and clinicopathological characteristics were obtained. Results 9/405 (2.2%) GIST patients were identified with RCC, with a mean follow-up of 9.2 [Range 3.8 – 28.4] years. 5/9 (55.6%) patients had RCC and GIST diagnosis within 6 months of each other. Mean RCC tumor size was 3.0 [Range 1.8 – 8] cm and 8/9 (88.9%) patients were RCC stage 1. 4/9 (44.4%) patients had papillary RCC (pRCC) histology, 5/9 (55.6%) had additional alternative malignancies, and 4/9 (44.4%) had primary small bowel GIST. Conclusions Our series suggests a possible association of RCC with GISTs. In addition, we found a high frequency of pRCC histology, alternative malignancies and small bowel GISTs in co-occurring RCC-GIST patients. Further investigation to identify genetic mutations, in this population, would assist in surveillance and treatment.

show abstract

“…2019; 21(10):e90287. two other malignancies in addition to GIST (14). In 2010, studying the survival ratio of 783 GIST patients showed that 24 of them (3.1%) had had more than two other primary malignancies (15).…”

Section: Discussionmentioning

confidence: 99%

Coincident of Gastrointestinal Stromal Tumor and Two Other Primary Malignancies: A Case Report

Kermani

Kakaei

Tarvirdizade

2019

Iran Red Crescent Med J

View full text Add to dashboard Cite

Introduction:Gastrointestinal Stromal Tumor (GIST) is an uncommon mesenchymal tumor of the gastrointestinal tract. It is rarely presented as Multiple Primary Malignancy Syndrome (MPMS) without an association with the familial syndromes. Case Presentation: A 63-year-old Iranian Azeri man admitted to a government hospital, affiliated to the Tabriz University of Medical Sciences, Tabriz, Iran, in 2012. The illness presented with complicated gastrointestinal problems with the diagnosis of GIST of the stomach, treated with imatinib. They family history and the screening tests of malignancies were negative, but the patient diagnosed with Squamous Cell Carcinoma (SCC) of the lower lip, leading to 28 courses of radiotherapy, followed by the recurrence of gastrointestinal symptoms, the GIST and SCC of the esophagus, that was also detected accidentally. Conclusions: Management of the multiple primary malignancy syndrome needs multidisciplinary teamwork. The study of MPMs, its etiology, and epidemiology can provide us proper ways of management.

show abstract

Coexistence of gastrointestinal stromal tumours (GIST) and malignant neoplasms of different origin: Prognostic implications

Cited by 54 publications

References 58 publications

Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors

Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors

The association of renal cell carcinoma with gastrointestinal stromal tumors

Coincident of Gastrointestinal Stromal Tumor and Two Other Primary Malignancies: A Case Report

Contact Info

Product

Resources

About